GlassScriptPhysician profile
Melissa Pinney
NPI 1407569627
$1,382.75
in general payments reported to CMS, 2019-2025
22 companies · $797 in 2025
The $797 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $292 · 2024: $293 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,382.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $278.95 | 2023-2025 | Zepbound, Mounjaro, Kisunla |
| Astrazeneca Pharmaceuticals LP | $199.30 | 2023-2025 | Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $102.33 | 2023-2024 | |
| Novo Nordisk INC | $99.95 | 2025 | Ozempic |
| Exact Sciences Corporation | $90.04 | 2025 | The Cologuard Plus Collection Kit |
| Abbvie INC. | $80.88 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $80.72 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.54 | 2023-2024 | Tradjenta, Jardiance |
| Cranial Technologies, INC | $63.91 | 2025 | Doc Band |
| Pfizer INC. | $50.02 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $46.37 | 2024 | |
| Paratek Pharmaceuticals, INC. | $26.91 | 2024 | Nuzyra |
| Corcept Therapeutics | $23.05 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $22.40 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $21.00 | 2023 | Keveyis |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $20.51 | 2025 | Apretude |
| Sanofi Pasteur INC. | $19.88 | 2023 | |
| Abbott Laboratories | $17.93 | 2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $17.83 | 2025 | Penmenvy, Bexsero |
| Hologic Sales and Service, LLC | $16.90 | 2024 | Aptima |
| Verona Pharma, INC. | $14.91 | 2025 | Ohtuvayre |
| Lundbeck LLC | $13.42 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Pinney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.